BG Medicine, Inc. (BGMD)
Stock Price:
$0.0208 USD
0.0013 (6.67%)
Updated Aug 13, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
235,445 |
| Revenue (ttm) |
1.57M |
| Net Income (ttm) |
-5.30M |
| Shares Out |
11.37M |
| EPS (ttm) |
-0.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$0.0208 |
| Previous Close |
$0.0195 |
| Change ($) |
0.0013 |
| Change (%) |
6.67% |
| Day's Open |
0.0207 |
| Day's Range |
0.0200 - 0.0208 |
| Day's Volume |
1,320 |
| 52-Week Range |
0.0071 - 0.0500 |
More Stats
| Market Cap |
235,445 |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
11.37M |
| Float |
8.31M |
| EPS (basic) |
-0.72 |
| EPS (diluted) |
-0.72 |
| FCF / Share |
-0.38 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
630,048 |
| Short Ratio |
2.66 |
| Short % of Float |
10.14% |
| Beta |
0.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.15 |
| PB Ratio |
n/a |
| Revenue |
1.57M |
| Operating Income |
-4.63M |
| Net Income |
-5.30M |
| Free Cash Flow |
-3.65M |
| Net Cash |
1.53M |
| Net Cash / Share |
0.13 |
| Gross Margin |
67.75% |
| Operating Margin |
-295.66% |
| Profit Margin |
-444.30% |
| FCF Margin |
-233.33% |
| ROA |
-75.95% |
| ROE |
-902.64% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
5.60
Current: $0.0208
High
5.60
Target: 5.60
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|
| Revenue | 1.57 | 2.79 | 4.07 | 2.82 | 1.63 | 0.82 | 8.49 | 14.58 | 8.98 |
| Revenue Growth | -43.81% | -31.57% | 44.69% | 72.28% | 99.51% | -90.35% | -41.77% | 62.32% | - |
| Gross Profit | 1.06 | 1.83 | 2.68 | 1.86 | 1.02 | 0.03 | 0.06 | 0.76 | 1.68 |
| Operating Income | -4.63 | -7.36 | -14.37 | -22.73 | -17.49 | -14.61 | -15.99 | -10.58 | -11.01 |
| Net Income | -5.30 | -8.06 | -15.85 | -23.77 | -17.58 | -17.16 | -16.14 | -15.07 | -11.39 |
| Shares Outstanding | 9.61 | 8.18 | 6.80 | 5.05 | 4.41 | 0.74 | 0.73 | 0.72 | 0.71 |
| Earnings Per Share | -0.72 | -0.99 | -2.33 | -4.72 | -4.00 | -24.48 | -23.36 | -22.08 | -16.56 |
| Operating Cash Flow | -3.67 | -8.17 | -15.29 | -21.33 | -14.97 | -11.42 | -17.98 | -9.60 | -3.92 |
| Capital Expenditures | 0.01 | - | -0.03 | -0.09 | -0.09 | -0.08 | -0.70 | -0.39 | -0.74 |
| Free Cash Flow | -3.65 | -8.17 | -15.32 | -21.42 | -15.06 | -11.49 | -18.68 | -9.99 | -4.66 |
| Cash & Equivalents | 1.53 | 4.12 | 7.75 | 13.18 | 24.44 | 2.43 | 10.39 | 33.24 | 0.00 |
| Total Debt | - | 2.96 | 7.31 | 9.86 | - | 6.37 | 1.25 | 2.47 | - |
| Net Cash / Debt | 1.53 | 1.16 | 0.44 | 3.32 | 24.44 | -3.95 | 9.14 | 30.77 | 0.00 |
| Assets | 2.13 | 5.23 | 9.35 | 15.24 | 26.11 | 7.03 | 12.63 | 35.22 | - |
| Liabilities | 1.52 | 4.67 | 10.42 | 14.93 | 5.22 | 12.34 | 5.47 | 14.30 | - |
| Book Value | -1.98 | 0.56 | -1.07 | 0.31 | 20.89 | -77.41 | -63.90 | -49.16 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
BG Medicine, Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Paul R. Sohmer |
Stock Information
| Ticker Symbol |
BGMD |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
OTCMKTS: BGMD |
| IPO Date |
February 4, 2011 |
Description
BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.